自体和异体CIK细胞联合树突状细胞治疗原发性肝癌研究  

Treatment of Primary Carcinoma of Liver with CIK and DC from Autologous and Homologous

作　　者：邓笑伟[1] 徐铭宝[1] 高锦[2] 莫晨[1] 黄燕萍[1] 杨葳[1] 吴晓娥[1] 

机构地区：[1]武警总医院干部病房二科,北京100039 [2]中国科学院生物物理研究所,北京100101

出　　处：《科技导报》2008年第7期51-53,共3页Science & Technology Review

摘　　要：为对癌症患者采用个体化治疗,用患者自体、同种异体外周血进行细胞因子诱导的杀伤细胞(Cytokine Induced Killer,CIK)及树突状细胞(Dendritic Cell,DC)扩增,并应用流式细胞术检测其CIK、DC-CIK表型,然后采取静脉回输、皮下淋巴结注射和肝动脉灌注多种方法,对原发性肝癌进行自体和异体的CIK细胞联合DC细胞治疗。结果显示:患者免疫功能提高,生活质量改善。为该类患者提供了一种有效的免疫治疗手段。In the individualized treatment of advanced liver cancer, Peripheral Blood Mononuclear Cells （PBMC） of autologous and homologous types were collected, and Cytokine Induced Killer （CIK） cells and Dendritic Cells （DC） were multiplied by being cultured with cytokine. The phenotypes of CIK and DC-CIK were analyzed by FACS. Then the patients of advanced primary carcinoma of liver were administrated by CIK in combination with DC through intravenous injection, hypodermic and hepatic artery catheter perfusion. Results show that immune function and life quality of the patient have significantly improved. Treatment of CIK in combination with DC from autologous and homologous cells provides a new and efficacious immunity therapeutic tool for advanced liver cancers.

关 键 词：CIK细胞 树突状细胞 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]